---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-118064"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:50:29.392955+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acurx reports Q3 net loss of $3.1M; ibezapolstat Phase 2 shows 96% cure rate, advancing to Phase 3

## Summary
- Net loss $3.1M ($0.24/diluted share) vs $3.5M ($0.32) in Q3 2022; cash $7.1M at Sept 30, 2023.
- Post-quarter warrant conversion raised $2.2M via ~680,000 shares issued.
- Ibezapolstat Phase 2 top-line: 96% (25/26) clinical cure rate at end of treatment; no safety concerns.
- Company preparing for End-of-Phase 2 FDA meeting and Phase 3 initiation.
- R&D expenses $1.3M in Q3 (down from $1.6M); G&A $1.8M (down from $2.0M).

## SEC filing metadata
- accession: 0001104659-23-118064
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/0001104659-23-118064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/tm2330757d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-118064
- JSON: https://secwatch.observer/filing/0001104659-23-118064.json
- Plain text: https://secwatch.observer/filing/0001104659-23-118064.txt

## Key facts
- Earnings Releases
  Acurx Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: net income $3.1 million or $0.24 per diluted share.
  - Period: third quarter ended September 30, 2023
  - Net income: $3.1 million or $0.24 per diluted share
  - Result: reported results
  source text: The Company reported a net loss of $3.1 million or $0.24 per diluted share for the three months ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736243/000110465923118064/0001104659-23-118064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.